期刊
JOURNAL OF INORGANIC BIOCHEMISTRY
卷 233, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jinorgbio.2022.111855
关键词
Cyclometalated iridium(III) complexes; Dithioformic acid; Anticancer; Apoptosis; Mitochondrial channel
资金
- Shandong Provincial Natural Science Foundation [ZR2021MH314, ZR20120MB102]
- Taishan Scholars Program
Four neutral cyclometalated iridium(III) dithioformic acid complexes were designed and synthesized, with favorable anticancer activity against non-small cell lung cancer cells through targeting mitochondria and inducing apoptosis.
Four neutral cyclometalated iridium(III) (Ir-III) dithioformic acid complexes ([(ppy)(2)Ir((SS)-S-boolean AND)], Ir1-Ir4) were designed and synthesized. Toxicity assay revealed that these complexes showed favorable anticancer activity, especially for human non-small cell lung cancer cells (A549). Ir1 exhibited the best anticancer activity (11.0 +/- 0.4 mu M) was about twice that of cisplatin, meanwhile, which could availably restrain A549 cells migration. Complexes could target mitochondria, induce a decrease in mitochondrial membrane potential (MMP), result in an increase of intracellular reactive oxygen species (ROS) and disruption of the cell cycle, and ultimately generate apoptosis. Western blotting experiment indicated that complexes could inhibit the expression of B cell CLL/lymphoma-2 protein (Bcl-2), induce the expression of BCL2-associated X protein (Bax) and lead to a massive release of Cytochrome C (Cyt-c), which amplified apoptosis signals by activating downstream pathway to promote apoptosis. All these confirmed the existence of mitochondrial anticancer channels for these complexes. Above all, cyclometalated iridium(III) dithioformic acid complexes possess the prospect of becoming a multifunctional cancer therapeutic platform, including mitochondria-targeted imaging, anti-migration, and anticancer agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据